Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series

Journal of Medicinal Chemistry

Volumn 56, Issue 17, 2013, Pages 6803-6818

  Taldone, Tony ^a   Patel, Pallav D ^a   Patel, Maulik ^a   Patel, Hardik J ^a   Evans, Christopher E ^a   Rodina, Anna ^a   Ochiana, Stefan ^a   Shah, Smit K ^a   Uddin, Mohammad ^a   Gewirth, Daniel ^b   Chiosis, Gabriela ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR;

ACCURACY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; FLUORESCENCE POLARIZATION; LIGAND BINDING; MATHEMATICAL COMPUTING; MOLECULAR DYNAMICS;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; FLUORESCENCE POLARIZATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR PROBES; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; SEQUENCE HOMOLOGY, AMINO ACID; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84884257315     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400619b     Document Type: Article

References (65)

1. Jhaveri, K.; Taldone, T.; Modi, S.; Chiosis, G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Biochim. Biophys. Acta 2012, 1823, 742-755
2. Biamonte, M. A.; Van de Water, R.; Arndt, J. W.; Scannevin, R. H.; Perret, D.; Lee, W. C. Heat shock protein 90: inhibitors in clinical trials J. Med. Chem. 2010, 53, 3-17
3. Chiosis, G.; Dickey, C. A.; Johnson, J. L. A global view of Hsp90 functions Nat. Struct. Mol. Biol. 2013, 20, 1-4
4. Taipale, M.; Jarosz, D. F.; Lindquist, S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights Nat. Rev. Mol. Cell Biol. 2010, 11, 515-528
5. Isaacs, J. S.; Xu, W.; Neckers, L. Heat shock protein 90 as a molecular target for cancer therapeutics Cancer Cell 2003, 3, 213-217
6. Marzec, M.; Eletto, D.; Argon, Y. GRP94: an HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum Biochim. Biophys. Acta 2012, 1823, 774-787
7. McLaughlin, M.; Vandenbroeck, K. The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery? Br. J. Pharmacol. 2011, 162, 328-345
8. Ni, M.; Lee, A. S. ER chaperones in mammalian development and human diseases FEBS Lett. 2007, 581, 3641-3651
9. Kang, B. H.; Plescia, J.; Dohi, T.; Rosa, J.; Doxsey, S. J.; Altieri, D. C. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network Cell 2007, 131, 257-270
10. Costantino, E.; Maddalena, F.; Calise, S.; Piscazzi, A.; Tirino, V.; Fersini, A.; Ambrosi, A.; Neri, V.; Esposito, F.; Landriscina, M. TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells Cancer Lett. 2009, 279, 39-46
11. Restall, I. J.; Lorimer, I. A. Induction of premature senescence by hsp90 inhibition in small cell lung cancer PLoS One 2010, 5, e11076
12. Rodina, A.; Vilenchik, M.; Moulick, K.; Aguirre, J.; Kim, J.; Chiang, A.; Litz, J.; Clement, C. C.; Kang, Y.; She, Y.; Wu, N.; Felts, S.; Wipf, P.; Massague, J.; Jiang, X.; Brodsky, J. L.; Krystal, G. W.; Chiosis, G. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer Nat. Chem. Biol. 2007, 3, 498-507
13. Duerfeldt, A. S.; Peterson, L. B.; Maynard, J. C.; Ng, C. L.; Eletto, D.; Ostrovsky, O.; Shinogle, H. E.; Moore, D. S.; Argon, Y.; Nicchitta, C. V.; Blagg, B. S. Development of a Grp94 inhibitor J. Am. Chem. Soc. 2012, 134, 9796-9804
14. Kang, B. H.; Plescia, J.; Song, H. Y.; Meli, M.; Colombo, G.; Beebe, K.; Scroggins, B.; Neckers, L.; Altieri, D. C. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90 J. Clin. Invest. 2009, 119, 454-464
15. v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 8324-8328
16. DeBoer, C.; Meulman, P. A.; Wnuk, R. J.; Peterson, D. H. Geldanamycin, a new antibiotic J. Antibiot. 1970, 23, 442-447
17. Schulte, T. W.; Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin Cancer Chemother. Pharmacol. 1998, 42, 273-279
18. Kasibhatla, S. R.; Hong, K.; Biamonte, M. A.; Busch, D. J.; Karjian, P. L.; Sensintaffar, J. L.; Kamal, A.; Lough, R. E.; Brekken, J.; Lundgren, K.; Grecko, R.; Timony, G. A.; Ran, Y.; Mansfield, R.; Fritz, L. C.; Ulm, E.; Burrows, F. J.; Boehm, M. F. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity J. Med. Chem. 2007, 50, 2767-2778
19. He, H.; Zatorska, D.; Kim, J.; Aguirre, J.; Llauger, L.; She, Y.; Wu, N.; Immormino, R. M.; Gewirth, D. T.; Chiosis, G. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90 J. Med. Chem. 2006, 49, 381-390
20. Bao, R.; Lai, C.-J.; Qu, H.; Wang, D.; Yin, L.; Zifcak, B.; Atoyan, R.; Wang, J.; Samson, M.; Forrester, J.; DellaRocca, S.; Xu, G.-X.; Tao, X.; Zhai, H.-X.; Cai, X.; Qian, C. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy Clin. Cancer Res. 2009, 15, 4046-4057
21. Huang, K. H.; Veal, J. M.; Fadden, R. P.; Rice, J. W.; Eaves, J.; Strachan, J.-P.; Barabasz, A. F.; Foley, B. E.; Barta, T. E.; Ma, W.; Silinski, M. A.; Hu, M.; Partridge, J. M.; Scott, A.; DuBois, L. G.; Freed, T.; Steed, P. M.; Ommen, A. J.; Smith, E. D.; Hughes, P. F.; Woodward, A. R.; Hanson, G. J.; McCall, W. S.; Markworth, C. J.; Hinkley, L.; Jenks, M.; Geng, L.; Lewis, M.; Otto, J.; Pronk, B.; Verleysen, K.; Hall, S. E. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents J. Med. Chem. 2009, 52, 4288-4305
22. Brough, P. A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J. E.; Cheung, K.-M. J.; Collins, I.; Davies, N. G. M.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Finch, H.; Fink, A.; Hayes, A.; Howes, R.; Hubbard, R. E.; James, K.; Jordan, A. M.; Lockie, A.; Martins, V.; Massey, A.; Matthews, T. P.; McDonald, E.; Northfield, C. J.; Pearl, L. H.; Prodromou, C.; Ray, S.; Raynaud, F. I.; Roughley, S. D.; Sharp, S. Y.; Surgenor, A.; Walmsley, D. L.; Webb, P.; Wood, M.; Workman, P.; Wright, L. 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer J. Med. Chem. 2008, 51, 196-218
23. Ying, W.; Du, Z.; Sun, L.; Foley, K. P.; Proia, D. A.; Blackman, R. K.; Zhou, D.; Inoue, T.; Tatsuta, N.; Sang, J.; Ye, S.; Acquaviva, J.; Ogawa, L. S.; Wada, Y.; Barsoum, J.; Koya, K. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy Mol. Cancer Ther. 2012, 11, 475-484
24. McLaughlin, S. H.; Ventouras, L. A.; Lobbezoo, B.; Jackson, S. E. Independent ATPase activity of Hsp90 subunits creates a flexible assembly platform J. Mol. Biol. 2004, 344, 813-826
25. Richter, K.; Soroka, J.; Skalniak, L.; Leskovar, A.; Hessling, M.; Reinstein, J.; Buchner, J. Conserved conformational changes in the ATPase cycle of human hsp90 J. Biol. Chem. 2008, 283, 17757-17765
26. Frey, S.; Leskovar, A.; Reinstein, J.; Buchner, J. The ATPase cycle of the endoplasmic chaperone Grp94 J. Biol. Chem. 2007, 282, 35612-35620
27. Rosser, M. F.; Nicchitta, C. V. Ligand interactions in the adenosine nucleotide-binding domain of the Hsp90 chaperone, GRP94. I. Evidence for allosteric regulation of ligand binding J. Biol. Chem. 2000, 275, 22798-22805
28. Leskovar, A.; Wegele, H.; Werbeck, N. D.; Buchner, J.; Reinstein, J. The ATPase Cycle of the Mitochondrial Hsp90 Analog Trap1 J. Biol. Chem. 2008, 283, 11677-11688
29. Llauger-Bufi, L.; Felts, S. J.; Huezo, H.; Rosen, N.; Chiosis, G. Synthesis of novel fluorescent probes for the molecular chaperone Hsp90 Bioorg. Med. Chem. Lett. 2003, 13, 3975-3978
30. Kim, J.; Felts, S.; Llauger, L.; He, H.; Huezo, H.; Rosen, N.; Chiosis, G. Development of a fluorescence polarization assay for the molecular chaperone Hsp90 J. Biomol. Screening 2004, 9, 375-381
31. Du, Y.; Moulick, K.; Rodina, A.; Aguirre, J.; Felts, S.; Dingledine, R.; Fu, H.; Chiosis, G. High-throughput screening fluorescence polarization assay for tumor-specific Hsp90 J. Biomol. Screening 2007, 12, 915-924
32. Howes, R.; Barril, X.; Dymock, B. W.; Grant, K.; Northfield, C. J.; Robertson, A. G.; Surgenor, A.; Wayne, J.; Wright, L.; James, K.; Matthews, T.; Cheung, K. M.; McDonald, E.; Workman, P.; Drysdale, M. J. A fluorescence polarization assay for inhibitors of Hsp90 Anal. Biochem. 2006, 350, 202-213
33. Moulick, K.; Clement, C. C.; Aguirre, J.; Kim, J.; Kang, Y.; Felts, S.; Chiosis, G. Synthesis of a red-shifted fluorescence polarization probe for Hsp90 Bioorg. Med. Chem. Lett. 2006, 16, 4515-4518
34. Lea, W. A.; Simeonov, A. Fluorescence Polarization Assays in Small Molecule Screening Expert Opin. Drug Discovery 2011, 6, 17-32
35. Jameson, D. M.; Ross, J. A. Fluorescence polarization/anisotropy in diagnostics and imaging Chem. Rev. 2010, 110, 2685-2708
36. Mayer, M. P. Gymnastics of molecular chaperones Mol. Cell 2010, 39, 321-331
37. Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F. U.; Pavletich, N. P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent Cell 1997, 89, 239-250
38. Prodromou, C.; Roe, S. M.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone Cell 1997, 90, 65-75
39. Immormino, R. M.; Kang, Y.; Chiosis, G.; Gewirth, D. T. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors J. Med. Chem. 2006, 49, 4953-4960
40. Brough, P. A.; Barril, X.; Borgognoni, J.; Chene, P.; Davies, N. G. M.; Davis, B.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Garcia-Echeverria, C.; Fromont, C.; Hayes, A.; Hubbard, R. E.; Jordan, A. M.; Jensen, M. R.; Massey, A.; Merrett, A.; Padfield, A.; Parsons, R.; Radimerski, T.; Raynaud, F. I.; Robertson, A.; Roughley, S. D.; Schoepfer, J.; Simmonite, H.; Sharp, S. Y.; Surgenor, A.; Valenti, M.; Walls, S.; Webb, P.; Wood, M.; Workman, P.; Wright, L. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3- d ]pyrimidine inhibitors of the Hsp90 molecular chaperone J. Med. Chem. 2009, 52, 4794-4809
41. Yun, T. J.; Harning, E. K.; Giza, K.; Rabah, D.; Li, P.; Arndt, J. W.; Luchetti, D.; Biamonte, M. A.; Shi, J.; Lundgren, K.; Manning, A.; Kehry, M. R. EC144, A Synthetic Inhibitor of Heat Shock Protein 90, Blocks Innate and Adaptive Immune Responses in Models of Inflammation and Autoimmunity J. Immunol. 2011, 186, 563-575
42. Barta, T. E.; Veal, J. M.; Rice, J. W.; Partridge, J. M.; Fadden, R. P.; Ma, W.; Jenks, M.; Geng, L.; Hanson, G. J.; Huang, K. H.; Barabasz, A. F.; Foley, B. E.; Otto, J.; Hall, S. E. Discovery of benzamide tetrahydro-4 H -carbazol-4-ones as novel small molecule inhibitors of Hsp90 Bioorg. Med. Chem. Lett. 2008, 18, 3517-3521
43. Immormino, R. M.; Metzger, L. E.; Reardon, P. N.; Dollins, D. E.; Blagg, B. S.; Gewirth, D. T. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design J. Mol. Biol. 2009, 388, 1033-1042
44. Shi, J.; Van de Water, R.; Hong, K.; Lamer, R. B.; Weichert, K. W.; Sandoval, C. M.; Kasibhatla, S. R.; Boehm, M. F.; Chao, J.; Lundgren, K.; Timple, N.; Lough, R.; Ibanez, G.; Boykin, C.; Burrows, F. J.; Kehry, M. R.; Yun, T. J.; Harning, E. K.; Ambrose, C.; Thompson, J.; Bixler, S. A.; Dunah, A.; Snodgrass-Belt, P.; Arndt, J.; Enyedy, I. J.; Li, P.; Hong, V. S.; McKenzie, A.; Biamonte, M. A. EC144 is a potent inhibitor of the heat shock protein 90 J. Med. Chem. 2012, 55, 7786-7795
45. Alexander, L. D.; Partridge, J. R.; Agard, D. A.; McAlpine, S. R. A small molecule that preferentially binds the closed conformation of Hsp90 Bioorg. Med. Chem. Lett. 2011, 21, 7068-7071
46. Schilb, A.; Riou, V.; Schoepfer, J.; Ottl, J.; Müller, K.; Chene, P.; Mayr, L. M.; Filipuzzi, I. Development and implementation of a highly miniaturized confocal 2D-FIDA-based high-throughput screening assay to search for active site modulators of the human heat shock protein 90beta J. Biomol. Screening 2004, 9, 569-577
47. Massey, A. J.; Schoepfer, J.; Brough, P. A.; Brueggen, J.; Chène, P.; Drysdale, M. J.; Pfaar, U.; Radimerski, T.; Ruetz, S.; Schweitzer, A.; Wood, M.; Garcia-Echeverria, C.; Jensen, M. R. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800 Mol. Cancer Ther. 2010, 9, 906-919
48. Eccles, S. A.; Massey, A.; Raynaud, F. I.; Sharp, S. Y.; Box, G.; Valenti, M.; Patterson, L.; Brandon, A. H.; Gowan, S.; Boxall, F.; Aherne, W.; Rowlands, M.; Hayes, A.; Martins, V.; Urban, F.; Boxall, K.; Prodromou, C.; Pearl, L.; James, K.; Matthews, T. P.; Cheung, K.-M.; Kalusa, A.; Jones, K.; McDonald, E.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Dymock, B.; Drysdale, M. J.; Finch, H.; Howes, R.; Hubbard, R. E.; Surgenor, A.; Webb, P.; Wood, M.; Wright, L.; Workman, P. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis Cancer Res. 2008, 68, 2850-2860
49. Taldone, T.; Gomes-DaGama, E. M.; Zong, H.; Sen, S.; Alpaugh, M. L.; Zatorska, D.; Alonso-Sabadell, R.; Guzman, M. L.; Chiosis, G. Synthesis of purine-scaffold fluorescent probes for heat shock protein 90 with use in flow cytometry and fluorescence microscopy Bioorg. Med. Chem. Lett. 2011, 21, 5347-5352
50. Lynch, B. A.; Loiacono, K. A.; Tiong, C. L.; Adams, S. E.; MacNeil, I. A. A Fluorescence Polarization Based Src-SH2 Binding Assay Anal. Biochem. 1997, 247, 77-82
51. Wu, P.; Brasseur, M.; Schindler, U. A High-Throughput STAT Binding Assay Using Fluorescence Polarization Anal. Biochem. 1997, 249, 29-36
52. Patel, P. D.; Yan, P.; Seidler, P. M.; Patel, H. J.; Sun, W.; Yang, C.; Que, N. S.; Taldone, T.; Finotti, P.; Stephani, R. A.; Gewirth, D. T.; Chiosis, G. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat. Chem. Biol. 2013; doi: 10.01038/nchembio.1335.
53. Taldone, T.; Zatorska, D.; Patel, P. D.; Zong, H.; Rodina, A.; Ahn, J. H.; Moulick, K.; Guzman, M. L.; Chiosis, G. Design, Synthesis and Evaluation of Small Molecule Hsp90 Probes Bioorg. Med. Chem. 2011, 19, 2603-2614
54. Dollins, D. E.; Warren, J. J.; Immormino, R. M.; Gewirth, D. T. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the Hsp90 chaperones Mol. Cell 2007, 28, 41-56
55. Felts, S. J.; Owen, B. A.; Nguyen, P.; Trepel, J.; Donner, D. B.; Toft, D. O. The Hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties J. Biol. Chem. 2000, 275, 3305-3312
56. Ge, J.; Normant, E.; Porter, J. R.; Ali, J. A.; Dembski, M. S.; Gao, Y.; Georges, A. T.; Grenier, L.; Pak, R. H.; Patterson, J.; Sydor, J. R.; Tibbitts, T. T.; Tong, J. K.; Adams, J.; Palombella, V. J. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17- demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90 J. Med. Chem. 2006, 49, 4606-4615
57. Lundgren, K.; Zhang, H.; Brekken, J.; Huser, N.; Powell, R. E.; Timple, N.; Busch, D. J.; Neely, L.; Sensintaffar, J. L.; Yang, Y.; McKenzie, A.; Friedman, J.; Scannevin, R.; Kamal, A.; Hong, K.; Kasibhatla, S. R.; Boehm, M. F.; Burrows, F. J. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90 Mol. Cancer Ther. 2009, 8, 921-929
58. Caldas-Lopes, E.; Cerchietti, L.; Ahn, J. H.; Clement, C. C.; Robles, A. I.; Rodina, A.; Moulick, K.; Taldone, T.; Gozman, A.; Guo, Y.; Wu, N.; de Stanchina, E.; White, J.; Gross, S. S.; Ma, Y.; Varticovski, L.; Melnick, A.; Chiosis, G. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 8368-8373
59. Chandarlapaty, S.; Sawai, A.; Ye, Q.; Scott, A.; Silinski, M.; Huang, K.; Fadden, P.; Partdrige, J.; Hall, S.; Steed, P.; Norton, L.; Rosen, N.; Solit, D. B. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers Clin. Cancer Res. 2008, 14, 240-248
60. Solit, D. B.; Zheng, F. F.; Drobnjak, M.; Munster, P. N.; Higgins, B.; Verbel, D.; Heller, G.; Tong, W.; Cardon-Cardo, C.; Agus, D. B.; Scher, H. I.; Rosen, N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts Clin. Cancer Res. 2002, 8, 986-993
61. Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. E. Structure-activity relationships in purine-based inhibitor binding to Hsp90 isoforms Chem. Biol. 2004, 6, 775-785
62. Immormino, R. M.; Dollins, D. E.; Shaffer, P. L.; Soldano, K. L.; Walker, M. A.; Gewirth, D. T. Ligand-induced conformational shift in the N-terminal domain of GRP94, an Hsp90 chaperone J. Biol. Chem. 2004, 279, 46162-46171
63. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749
64. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening J. Med. Chem. 2004, 47, 1750-1759
65. Patel, P. D.; Patel, M. R.; Kaushik-Basu, N.; Talele, T. T. 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors J. Chem. Inf. Model. 2008, 48, 42-55